Taku Shigesawa

Sapporo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.

Journal: PloS one

Published: March 30, 2022

Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patients.

Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patients.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: November 18, 2021

The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease.

The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: September 21, 2021

Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication.

Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication.

Journal: Scientific reports

Published: September 13, 2021

FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma.

FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma.

Journal: Cancer biology & therapy

Published: July 05, 2021

Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI.

Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI.

Journal: Cancers

Published: July 05, 2021

Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.

Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: April 12, 2021

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.

Journal: PloS one

Published: March 31, 2021

Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy.

Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy.

Journal: World journal of gastrointestinal oncology

Published: March 29, 2021

Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C.

Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C.

Journal: Scientific reports

Published: January 08, 2021

Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass.

Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass.

Journal: Journal of viral hepatitis

Published: December 22, 2020

Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.

Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma.

Journal: PloS one

Published: December 22, 2020

Showing 1-12 of 30

Last Updated: 09/26/2026